Impact of IgG subclass on monoclonal antibody developability

References

• Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. mAbs. 2022;14:2014296. doi:10.1080/19420862.2021.2014296. PMID: 35030985.
   PubMed Web of Science ®Google Scholar
• Delidakis G, Kim JE, George K, Georgiou G. Improving antibody therapeutics by manipulating the Fc domain: immunological and structural considerations. Annu Rev Biomed Eng. 2022;24:249–12. doi:10.1146/annurev-bioeng-082721-024500. PMID: 35363537.
   PubMed Web of Science ®Google Scholar
• Hari SB, Lau H, Razinkov VI, Chen S, Latypov RF. Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. Biochemistry. 2010;49:9328–38. doi:10.1021/bi100841u. PMID: 20843079.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Ito T, Endo R, Nakagawa K, Sawa E, Wakamatsu K. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies. Biol Pharm Bull. 2010;33:1413–17. doi:10.1248/bpb.33.1413. PMID: 20686240.
   PubMed Web of Science ®Google Scholar
• Skamris T, Tian X, Thorolfsson M, Karkov HS, Rasmussen HB, Langkilde AE, Vestergaard B. Monoclonal antibodies follow distinct aggregation pathways during production-relevant acidic incubation and neutralization. Pharm Res. 2016;33:716–28. doi:10.1007/s11095-015-1821-0. PMID: 26563206.
   PubMed Web of Science ®Google Scholar
• Saito S, Namisaki H, Hiraishi K, Takahashi N, Iida S. Engineering a human IgG2 antibody stable at low pH. Protein Sci. 2020;29:1186–95. doi:10.1002/pro.3852. PMID: 32142185.
   PubMed Web of Science ®Google Scholar
• Mazzer AR, Perraud X, Halley J, O’hara J, Bracewell DG. Protein a chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold. J Chromatogr A. 2015;1415:83–90. PMID: 26346187. doi:10.1016/j.chroma.2015.08.068.
   PubMed Web of Science ®Google Scholar
• Jin W, Xing Z, Song Y, Huang C, Xu X, Ghose S, Li ZJ. Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification. mAbs. 2019;11:1479–91. doi:10.1080/19420862.2019.1658493. PMID: 31441367.
   PubMed Web of Science ®Google Scholar
• Brezski RJ, Oberholtzer A, Strake B, Jordan RE. The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge. mAbs. 2011;3:558–67. doi:10.4161/mabs.3.6.18119. PMID: 22123056.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Annaka H, Konno S, Kumagai I, Asano R. Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance. Sci Rep. 2018;8:17253. doi:10.1038/s41598-018-35489-y. PMID: 30467410.
   PubMed Web of Science ®Google Scholar
• Ito T, Tsumoto K. Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress. Protein Sci. 2013;22:1542–51. doi:10.1002/pro.2340. PMID: 23963869.
   PubMed Web of Science ®Google Scholar
• Tian X, Langkilde AE, Thorolfsson M, Rasmussen HB, Vestergaard B. Small-angle x-ray scattering screening complements conventional biophysical analysis: comparative structural and biophysical analysis of monoclonal antibodies IgG1, IgG2, and IgG4. J Pharm Sci. 2014;103:1701–10. doi:10.1002/jps.23964. PMID: 24700358.
   PubMed Web of Science ®Google Scholar
• Alekseychyk L, Su C, Becker GW, Treuheit MJ, Razinkov VI., Razinkov VI. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations. J Biomol Screen. 2014;19:1290–301. PMID: 25023322. doi:10.1177/1087057114542431.
   PubMedGoogle Scholar
• Neergaard MS, Nielsen AD, Parshad H, Van De Weert M. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass. J Pharm Sci. 2014;103:115–27. doi:10.1002/jps.23788. PMID: 24282022.
   PubMed Web of Science ®Google Scholar
• Levy NE, Valente KN, Choe LH, Lee KH, Lenhoff AM. Identification and characterization of host cell protein product-associated impurities in monoclonal antibody bioprocessing. Biotechnol Bioeng. 2014;111:904–12. doi:10.1002/bit.25158. PMID: 24254318.
   PubMed Web of Science ®Google Scholar
• Tang Y, Cain P, Anguiano V, Shih JJ, Chai Q, Feng Y. Impact of IgG subclass on molecular properties of monoclonal antibodies. mAbs. 2021;13:1993768. doi:10.1080/19420862.2021.1993768. PMID: 34763607.
   PubMed Web of Science ®Google Scholar
• Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15:289–302. PMID: 11520463. doi:10.1016/s1074-7613(01)00183-2.
   PubMed Web of Science ®Google Scholar
• Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, Pedley B, Adair JR. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993;30:105–08. doi:10.1016/0161-5890(93)90432-b. PMID: 8417368.
   PubMed Web of Science ®Google Scholar
• Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. Intrachain disulfide bond in the core hinge region of human IgG4. Protein science: a publication of the protein society. Protein Sci. 1997;6:407–15. PMID: 9041643. doi:10.1002/pro.5560060217.
   PubMed Web of Science ®Google Scholar
• Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol. 2001;38:1–8. doi:10.1016/s0161-5890(01)00050-5. PMID: 11483205.
   PubMed Web of Science ®Google Scholar
• Li X, Wang F, Li H, Richardson DD, Roush DJ. The measurement and control of high-risk host cell proteins for polysorbate degradation in biologics formulation. Antib Ther. 2022;5:42–54. doi:10.1093/abt/tbac002. PMID: 35155990.
   PubMedGoogle Scholar
• Zhang S, Riccardi C, Kamen D, Reilly J, Mattila J, Bak H, Xiao H, Li N. Identification of the specific causes of polysorbate 20 degradation in monoclonal antibody formulations containing multiple lipases. Pharm Res. 2022;39:75–87. doi:10.1007/s11095-021-03160-3. PMID: 34981317.
   PubMed Web of Science ®Google Scholar
• Szkodny AC, Lee KH. Biopharmaceutical manufacturing: historical perspectives and future directions. Annual review of chemical and biomolecular engineering. Annu Rev Chem Biomol Eng. 2022;13:141–65. PMID: 35300518. doi:10.1146/annurev-chembioeng-092220-125832.
   PubMed Web of Science ®Google Scholar
• Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016;100:3451–61. doi:10.1007/s00253-016-7388-9. PMID: 26936774.
   PubMed Web of Science ®Google Scholar
• Le Basle Y, Chennell P, Tokhadze N, Astier A, Sautou V. Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci. 2020;109:169–90. doi:10.1016/j.xphs.2019.08.009. PMID: 31465737.
   PubMed Web of Science ®Google Scholar
• Ayyar BV, Arora S, Ravi SS. Optimizing antibody expression: the nuts and bolts. Meth (San Diego Calif). 2017;116:51–62. doi:10.1016/j.ymeth.2017.01.009. PMID: 28163103.
   PubMed Web of Science ®Google Scholar
• Fischer SK, Cheu M, Peng K, Lowe J, Araujo J, Murray E, McClintock D, Matthews J, Siguenza P, Song A. Specific immune response to phospholipase B-Like 2 protein, a host cell impurity in Lebrikizumab clinical material. Aaps J. 2017;19:254–63. doi:10.1208/s12248-016-9998-7. PMID: 27739010.
   PubMed Web of Science ®Google Scholar
• Gao SX, Zhang Y, Stansberry-Perkins K, Buko A, Bai S, Nguyen V, Brader ML. Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity. Biotechnol Bioeng. 2011;108:977–82. doi:10.1002/bit.22982. PMID: 21404269.
   PubMed Web of Science ®Google Scholar
• Chiu J, Valente KN, Levy NE, Min L, Lenhoff AM, Lee KH. Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations. Biotechnol Bioeng. 2017;114:1006–15. doi:10.1002/bit.26237. PMID: 27943242.
   PubMed Web of Science ®Google Scholar
• Hall T, Sandefur SL, Frye CC, Tuley TL, Huang L. Polysorbates 20 and 80 degradation by group XV lysosomal phospholipase A2 isomer X1 in monoclonal antibody formulations. J Pharm Sci. 2016;105:1633–42. doi:10.1016/j.xphs.2016.02.022. PMID: 27056628.
   PubMed Web of Science ®Google Scholar
• Plomp R, Ruhaak LR, Uh HW, Reiding KR, Selman M, Houwing-Duistermaat JJ, Slagboom PE, Beekman M, Wuhrer M. Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. Sci Rep. 2017;7:12325. doi:10.1038/s41598-017-12495-0. PMID: 28951559.
   PubMed Web of Science ®Google Scholar
• de Haan N, Reiding KR, Krištić J, Hipgrave Ederveen AL, Lauc G, Wuhrer M. The N-Glycosylation of Mouse Immunoglobulin G (IgG)-fragment crystallizable differs between IgG subclasses and strains. Front Immunol. 2017;8:608. PMID: 28620376. doi:10.3389/fimmu.2017.00608.
   PubMed Web of Science ®Google Scholar
• Lund J, Takahashi N, Nakagawa H, Goodall M, Bentley T, Hindley SA, Tyler R, Jefferis R. Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs. Mol Immunol. 1993;30:741–48. doi:10.1016/0161-5890(93)90145-2. PMID: 8502242.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Joubert MK, Polozova A, De Guzman R, Lakamsani K, Kinderman F, Xiang D, Shami A, Miscalichi N, Flynn GC, et al. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity. Biotechnol Prog. 2020;36:e3045. PMID: 32627435. doi:10.1002/btpr.3045.
   PubMed Web of Science ®Google Scholar
• Thomann M, Reckermann K, Reusch D, Prasser J, Tejada ML. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol. 2016;73:69–75. PMID: 27058641. doi:10.1016/j.molimm.2016.03.002.
   PubMed Web of Science ®Google Scholar
• Aoyama M, Hashii N, Tsukimura W, Osumi K, Harazono A, Tada M, Kiyoshi M, Matsuda A, Ishii-Watabe A. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies. mAbs. 2019;11:826–36. doi:10.1080/19420862.2019.1608143. PMID: 30990348.
   PubMed Web of Science ®Google Scholar
• Chow CK, Allan BW, Chai Q, Atwell S, Lu J. Therapeutic antibody engineering to improve viscosity and phase separation guided by crystal structure. Mol Pharm. 2016;13:915–23. doi:10.1021/acs.molpharmaceut.5b00817. PMID: 26849155.
   PubMed Web of Science ®Google Scholar
• Mason BD, Zhang L, Remmele RL Jr., Zhang J. Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid-liquid phase separation. J Pharm Sci. 2011;100:4587–96. doi:10.1002/jps.22650. PMID: 21638285.
   PubMed Web of Science ®Google Scholar
• Kingsbury JS, Saini A, Auclair SM, Fu L, Lantz MM, Halloran KT, Calero-Rubio C, Schwenger W, Airiau CY, Zhang J, et al. A single molecular descriptor to predict solution behavior of therapeutic antibodies. Sci Adv. 2020;6:eabb0372. PMID: 32923611. doi:10.1126/sciadv.abb0372.
   PubMed Web of Science ®Google Scholar
• Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun. 2007;355:751–57. doi:10.1016/j.bbrc.2007.02.042. PMID: 17321501.
   PubMed Web of Science ®Google Scholar
• Heads JT, Adams R, D’hooghe LE, Page MJ, Humphreys DP, Popplewell AG, Lawson AD, Henry AJ. Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture. Protein Sci. 2012;21:1315–22. doi:10.1002/pro.2118. PMID: 22761163.
   PubMed Web of Science ®Google Scholar
• Franey H, Brych SR, Kolvenbach CG, Rajan RS. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates. Protein Sci. 2010;19:1601–15. doi:10.1002/pro.434. PMID: 20556807.
   PubMed Web of Science ®Google Scholar
• Schön A, Freire E. Reversibility and irreversibility in the temperature denaturation of monoclonal antibodies. Anal Biochem. 2021;626:114240. PMID: 33964250. doi:10.1016/j.ab.2021.114240.
   PubMed Web of Science ®Google Scholar
• Vlasak J, Ionescu R. Fragmentation of monoclonal antibodies. mAbs. 2011;3:253–63. doi:10.4161/mabs.3.3.15608. PMID: 21487244.
   PubMed Web of Science ®Google Scholar
• Valliere-Douglass J, Jones L, Shpektor D, Kodama P, Wallace A, Balland A, Bailey R, Zhang Y. Separation and characterization of an IgG2 antibody containing a cyclic imide in CDR1 of light chain by hydrophobic interaction chromatography and mass spectrometry. Anal Chem. 2008;80:3168–74. doi:10.1021/ac702245c. PMID: 18355059.
   PubMed Web of Science ®Google Scholar
• Nowak C, Kc J, Md S, Katiyar A, Bhat R, Sun J, Ponniah G, Neill A, Mason B, Beck A, et al. Forced degradation of recombinant monoclonal antibodies: a practical guide. mAbs. 2017;9:1217–30. PMID: 28853987. doi:10.1080/19420862.2017.1368602.
   PubMed Web of Science ®Google Scholar
• Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr Pharm Biotechnol. 2008;9:468–81. doi:10.2174/138920108786786402. PMID: 19075686.
   PubMed Web of Science ®Google Scholar
• Lu X, Machiesky LA, De Mel N, Du Q, Xu W, Washabaugh M, Jiang XR, Wang J. Characterization of IgG1 Fc deamidation at asparagine 325 and its impact on antibody-dependent cell-mediated cytotoxicity and FcγRIIIa binding. Sci Rep. 2020;10:383. doi:10.1038/s41598-019-57184-2. PMID: 31941950.
   PubMed Web of Science ®Google Scholar
• Yan Q, Huang M, Lewis MJ, Hu P. Structure based prediction of asparagine deamidation propensity in monoclonal antibodies. mAbs. 2018;10:901–12. doi:10.1080/19420862.2018.1478646. PMID: 29958069.
   PubMed Web of Science ®Google Scholar
• Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol. 2000;37:697–706. doi:10.1016/s0161-5890(00)00105-x. PMID: 11275255.
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Mody N, Lu X, Kuhn ML, Wu H, Dall’acqua WF, Tsui P. An “Fc-Silenced” IgG1 format with extended half-life designed for improved stability. J Pharm Sci. 2017;106:1008–17. doi:10.1016/j.xphs.2016.12.023. PMID: 28057542.
   PubMed Web of Science ®Google Scholar
• Tam SH, McCarthy SG, Armstrong AA, Somani S, Wu SJ, Liu X, Gervais A, Ernst R, Saro D, Decker R, et al. Functional. Biophysical, and structural characterization of human IgG1 and IgG4 Fc variants with ablated immune functionality. Antibodies (Basel, Switzerland), 2017; Vol. 6. 10.3390/antib6030012. PMID: 31548527
   PubMedGoogle Scholar
• Huang L, Wang N, Mitchell CE, Brownlee T, Maple SR, De Felippis MR. A novel sample preparation for shotgun proteomics characterization of HCPs in antibodies. Anal Chem. 2017;89:5436–44. doi:10.1021/acs.analchem.7b00304. PMID: 28414239.
   PubMed Web of Science ®Google Scholar